Skip to main content
Sign In

University of Colorado Denver

​​​​​​​​​ ​
 

Clinical Pharmacy

Materia Medica


Materia Medica is a monthly newsletter published by the University of Colorado's Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Clinical Pharmacy. The primary objective of the newsletter is to educate health care professionals by providing focused reviews of new drug approvals and updates on the pharmacologic management of common disease states. The newsletter is directed towards primary care practitioners, including primarily physicians and pharmacists. Since its inception in 2012, Materia Medica has been written by fourth year pharmacy students while on their Ambulatory Care rotation at Internal Medicine Anschutz or Internal Medicine Lowry.

Materia Medica is no longer in publication. You may download past issues via the links below.

Issues

Volume 2, Issue 7 (December 2013)
· New influenza vaccines for the 2013-2014 season
· Could a nicotine vaccine be the groundbreaking solution to nicotine dependence?

Volume 2, Issue 6 (November 2013)
· Dileneating treatment options in the setting of male hypogonadism
· Comparative efficacy and safety of the GLP-1 agonists for the treatment of type 2 diabetes mellitus

Volume 2, Issue 5 (October 2013)
· Roflumilast (Daliresp®): A selective phosphodiesterase-4 inhibitor for the prevention of acute exacerbations of chronic obstructive pulmonary disease
· Apixaban (Eliquis®) for oral anticoagulation in nonvalvular atrial fibrillation

Volume 2, Issue 4 (September 2013)
· Tapentadol (Nucynta®) for the treatment of pain
· Diabetes and depression: Patient care impact and management options

Volume 2, Issue 3 (August 2013)
· Ospemifene (Osphena®): A new treatment for dyspareunia and vaginal atrophy
· News about an old vaccine: Current recommendations for pneumococcal vaccination

Volume 2, Issue 2 (July 2013)
· Canagliflozin (Invokana®): A Novel Agent for the Treatment of Type 2 Diabetes
· Treatment of Menopausal Vasomotor Symptoms: Phytoestrogens and Hormone Replacement Therapy

Volume 2, Issue 1 (June 2013)
· Adult immunizations for immunocompromised patients in the primary care setting
· Perampanel (Fycompa®): A novel anti-epileptic drug

Volume 1, Issue 12 (May 2013)
· Antiplatelet therapies to prevent thrombosis of recently placed coronary stents
· Clinical pearls of oral contraceptives

Volume 1, Issue 11 (April 2013)
· Benzodiazepine Use and Discontinuation in Patients with Psychiatric Disorders
· Insomnia Management with Non- Benzodiazepine Sedative Hypnotics in the Primary Care Setting

Volume 1, Issue 10 (March 2013)
· Acute bacterial rhinosinusitis: Applying the 2012 IDSA Clinical Practice Guidelines
· Metformin: Optimal dosing and myths surrounding lactic acidosis

Volume 1, Issue 9 (February 2013)
· Mirabegron: A Novel Treatment for Overactive Bladder
· Risks of NSAIDs and NSAID Use in High-Risk Patients

Volume 1, Issue 8 (January 2013)
· Bipolar Disorder: Medication Management in Primary Care
· Aclidinium Bromide (Tudorza Pressair®): A Novel Long-Acting Antimuscarinic for COPD

Volume 1, Issue 7 (December 2012)
· Lorcaserin: A Novel Weight-Loss Agent
· Probiotics for the Prevention of Antibiotic Associated Diarrhea in Adult Patients

Volume 1, Issue 6 (November 2012)
· Pain Treatment with Opioids in the Primary Care Setting
· Azilsartan medoxomil/Chlorthalidone in Patients with Hypertension

Volume 1, Issue 5 (October 2012)
· Fidaxomicin: A new oral macrolide antibiotic for treatment of Clostridium difficile-associated diarrhea
· Timing of warfarin monitoring and efficacy of vitamin K as a reversal agent

Volume 1, Issue 4 (September 2012)
· Phentermine/Topiramate (Qsymia®) for the treatment of obesity
· Practice considerations for 2nd generation sulfonylureas

Volume 1, Issue 3 (August 2012)
· Lingaliptin (Tradjenta®): A New DPP-4 Inhibitor for Type 2 Diabetes
· Statin Therapy to Achieve Cholesterol and Non-cholesterol Goals of Decreased Morbidity and Mortality

Volume 1, Issue 2 (July 2012)
· The Pioglitazone Controversy: Practice Implications
· Bydureon®: A New Once-Weekly GLP-1 Agonist for Type 2 DM

Volume 1, Issue 1 (June 2012)
· The Use of Rivaroxaban in Nonvalvular Atrial Fibrillation

​​